Mexico Launches Phase 3 Study For Chinese COVID-19 Vaccine

Tianjin, China, based CanSino Biologics Inc. announced that it has launched the Phase III clinical trial for the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV") in Mexico and has successfully vaccinated the first group of subjects. This late-stage clinical study announced on November 7, 2020, aims to recruit a total number of 15,000 participants to further demonstrate the Ad5-nCoV vaccine candidate's efficacy.

Dr. Xuefeng Yu, Chairman, and CEO of CanSinoBIO stated in a press release, “Launching the Ad5-nCoV study in Mexico represents another milestone... and we are delighted to collaborate with the authorities that make this study possible."

On October 16, 2020, CanSinoBIO signed an advance purchase agreement with the Mexican government to supply 35 million doses of COVID-19 vaccine.